An application for an IPO for NASDAQ has been filed by Passage BIO, a company specializing in the production of genetic drugs for the treatment of rare monogenic (single-gene mutations) diseases of the central nervous system.
The initial placement volume is $ 125 million.
Underwriters: J.P. Morgan / Goldman Sachs / Cowen
▪ This year, Passage plans to begin its first clinical trial and another 2 in 2021.
▪ The first gene therapy drug approved by the FDA for commercial use was the Luxturna product for the treatment of vision loss (2018), after which the developer was purchased for $ 4.3 billion.
▪ Passage PBGM01 is intended for patients with childhood gangliosidosis, the most severe type of condition that causes progressive destruction of neurons in the brain and spinal cord. The company intends to request permission from the FDA to conduct human testing in the first half of 2020, after which a phase 1/2 test will begin in the second half of the year.
▪ As of December 31, the company announced that it had raised $ 225.5 million, the share capital on the balance sheet is $ 158.9 million. The largest shareholders of the company are OrbiMed (19.6%), Versant Ventures (14.8%) and Frazier Life Sciences ( 13.9%).
▪ The company collaborates in strategic research with the University of Pennsylvania.
▪ The market for treating the central nervous system is estimated at $ 129 billion by 2025.
We draw your attention to the fact that the last 5 IPO transactions from the sector of medicine and biotechnology, currently show a yield in the range of 53.4%.